Oncology Community Unites to Bring Innovation to Patients With Cancer

September 2020.

Some of the most exciting new data at this year’s congress included advancements in lung cancer, breast cancer, genitourinary cancers, and gastrointestinal cancers. Several experts spoke with Targeted Oncology to share their thoughts on some of the most impactful abstracts from the 2020 ESMO Congress.

Breast Cancer

During the 2020 ESMO Congress, a number of studies were presented in the breast cancer field, but some of the most exciting data in this space revolved around targeted therapies. Several agents demonstrated promising data in clinical trials across a variety of subgroups of patients with breast cancer.

“There was good new data in breast cancer, and there were some less good or maybe contrasting results in some of the trials,” said Vorobiof. “I think from the breast cancer point of view, there were [many] interesting data, and some of them will become standard treatments, in the near future.”

Continue Reading >

More Articles

Equiva to integrate Belong.Life’s AI health mentors

US-based Equiva and Belong.Life have entered a partnership for the integration of the latter’s conversational…

Belong.Life and Equiva bring AI mentors to healthcare providers

Belong.life, the GenAI patient engagement solution, has announced a strategic partnership with Equiva, a US-based digital…

Conversational AI Partnership Expands Access for Equiva and Belong.Life

Revolutionizing Patient Care Through Conversational AI Integration Imagine having a reliable guide by your side…
Skip to content